Title : Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia.

Pub. Date : 2019 Apr 2

PMID : 31069015






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Activating internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations in Fms-like tyrosine kinase 3 (FLT3) occur in approximately 30% of patients with acute myeloid leukemia (AML), and confer a poor prognosis with standard cytarabine/anthracycline or azacitidine-based chemotherapy regimens. Azacitidine fms related receptor tyrosine kinase 3 Homo sapiens
2 Activating internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations in Fms-like tyrosine kinase 3 (FLT3) occur in approximately 30% of patients with acute myeloid leukemia (AML), and confer a poor prognosis with standard cytarabine/anthracycline or azacitidine-based chemotherapy regimens. Azacitidine fms related receptor tyrosine kinase 3 Homo sapiens